SLC5A2 and diabetes mellitus: Compared to the past two decades, medical treatments as well as healthcare systems have evolved to include a considerably wider range of treatment options, such as multidisciplinary clinics, SGLT2-inhibitors, GLP1-RA, and an increased use of CGM, as presented by the American Diabetes Association in 2024 (14).